产品编号:A149
产品描述:Anti-Human Acinus(Intermediate Domain)
反应种属:human
实验方法:IHC, WB
标记:
规格:0.1mg
供应商:leinco
价格(RMB):5370.00
订购:
说明书:
Rabbit Anti-Human Acinus
Purified No Carrier Protein
(Apoptotic Chromatin condensation Inducer in the Nucleus)
Polyclonal Antibody
Prod. No.: A149
Host: Rabbit
Conc.: 0.5 mg/ml
Pkg. Size: 1 mg, 0.1 mg, 0.5 mg
Storage: 2-8°C
Description
Specificity:
Rabbit Anti-Human Acinus (Intermediate Domain) recognizes an epitope in the intermediate domain of Human Acinus. This polyclonal antibody was purified using immobilized peptide affinity chromatography.
Background:
Chromatin condensation and nuclear fragmentation (CCNF) is the hallmark of apoptosis. CCNF is triggered by the activation of members of caspase family, caspase activated DNase (CAD/DFF40), and several novel proteins including AIF and CIDE . A new inducer of chromatin condensation was recently identified and designated Acinus (for apoptotic chromatin condensation inducer in the nucleus). Acinus is cleaved by caspase-3 and an additional unknown protease generating a small active peptide p17, which causes chromatin condensation in vitro when it is added to purified nuclei. Acinus also induces apoptotic chromatin condensation in cells. Acinus is ubiquitously expressed. Three different spliced forms of Acinus have been identified in human and mouse and designated AcinusL, AcinusS and AcinusS’.2
Known Species Cross Reactivity: Hu+
Immunogen
Acinus (Intermediate Domain) Blocking Peptide (Leinco Prod. No.: A167)
Blocking Peptide
Acinus (Intermediate Domain) Blocking Peptide (Leinco Prod. No.: A167)
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Stability
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Reported Applications
IHC (NBF/Par.), WB
IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 5 µg/ml. The recommended secondary antibody for IHC is Goat Anti-Rabbit IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: R1190). For chromogenic detection with high signal and low background use 3, 3'-Diaminobenzidine Tetrahydrochloride (DAB) Substrate Kit (Leinco Prod. No.: D100) or Optional Metal Enhanced DAB Substrate Kit (Leinco Prod. No.: K107).
Western Blotting: To detect Human Acinus this polyclonal antibody can be used at a concentration of 0.5 - 1.0 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as Goat Anti-Rabbit IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: R1190) and a chromogenic substrate such as TMB HRPO Membrane/IHC Substrate UltraSensitive™ One Component "Ready Use" (Leinco Prod. No.: T343). The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is K562 Whole Cell Lysate (Leinco Prod. No.: K128).
References
1. Zamzami N, Kroemer G. Condensed matter in cell death. Nature 1999 ;401:127-8.
Related Products
Acinus (Intermediate Domain) Blocking Peptide (Leinco Prod. No.: A167)
Goat Anti-Rabbit IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: R1190)
3, 3'-Diaminobenzidine Tetrahydrochloride (DAB) Substrate Kit (Leinco Prod. No.: D100)
Optional Metal Enhanced DAB Substrate Kit (Leinco Prod. No.: K107)
TMB HRPO Membrane/IHC Substrate UltraSensitive™ One Component "Ready Use" (Leinco Prod. No.: T343)
K562 Whole Cell Lysate (Leinco Prod. No.: K128)
Acinus (C-Terminus-1) Blocking Peptide (Leinco Prod. No.: A165)
Anti-Human Acinus (C--Terminus 1) (Leinco Prod. No.: A147)
PN:
Acinus (N-Terminus) Blocking Peptide (Leinco Prod. No.: A168)
Acinus (C-Terminus 2) Blocking Peptide (Leinco Prod. No.: A166)
Anti-Human Acinus (C-Terminus 2) (Leinco Prod. No.: A148)
Anti-Human Acinus (N-Terminus) (Leinco Prod. No.: A150)
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
